In the hormone receptor-positive subgroup, HER2-low tumor had longer LRFS than HER2-zero tumor (univariate analysis, Bonferroni corrected p = 0.053, Supplementary Figure S4A; multivariate analysis, p = 0.023). Here, ERBB2 is linked to neoplasm.